1100 NEW YORK AVENUE, N.W. . WASHINGTON, D.C. 20005-3934

PHONE: (202) 371-2600 . FACSIMILE: (202) 371-2540 . www.skgf.com

SREENE STERNE ROBORTO GREENE STE JORGE A. GOLDSTEIN SAMUEL L. FOX\*\*\* DAVID K.S. CORNWELL ROBERT W. ESMOND TRACY-GENE G. DURKIN MICHELE A. CIMBALA MICHAEL B. RAY ROBERT E. SOKOHL ERIC K. STEFFE MICHAEL Q. LEE STEVEN R. LUDWIG

JOHN M. COVERT LINDA E. ALCORN ROBERT C. MILLONIG MICHAEL V. MESSINGER JUDITH U. KIM
TIMOTHY J. SHEA, JR. PATRICK E. GARRETT JEFFREY T. HELVEY\* HEIDI L. KRAUS JEFFREY R. KURIN PATRICK D. O'BRIEN LAWRENCE B. BUGAISKY CRYSTAL D. SAYLES

EDWARD W. YEE ALBERT L. FERRO\* DONALD R. BANOWIT PETER A. JACKMAN MOLLY A. MCCALL TERESA U. MEDLER JEFFREY S. WEAVER
KENDRICK P. PATTERSON DONALD J. FEATHERSTONE VINCENT L. CAPUANO JOHN A. HARROUN\*
ALBERT J. FASULO III\* ELDORA ELLISON FLOYD\*

W. RUSSELL SWINDELL THOMAS C. FIALA
BRIAN J. DEL BUONO\* VIRGIL L. BEASTON\* RYAN J. STAMPER\*
REGINALD D. LUCAS\* THEODORE A. WOOD ELIZABETH J. HAANES BRUCE E. CHALKER JOSEPH S. OSTROFF KAREN R. MARKOWICZ SUZANNE E. ZISKA\*\* ANDREA J. KAMAGE\*\*

NANCY J. LEITH\*\* JOSEPH M. CONRAD, III\*\* DOUGLAS M. WILSON\*\* ANN E. SUMMERFIELD\*\* CYNTHIA M. BOUCHEZ\*\*
HELENE C. CARLSON\*\* GABY L. LONGSWORTH\*\* DUSTIN T. JOHNSON\*\*
MATTHEW J. DOWD\*\* AARON L. SCHWARTZ\*\*

LIMITED TO MATTERS AND PROCEEDINGS BEFORE
FEDERAL COURTS & AGENCIES
REGISTERED PATENT AGENT \*\*\*SENIOR COUNSEL

January 22, 2002



**WRITER'S DIRECT NUMBER:** (202) 371-2582 **INTERNET ADDRESS:** PJACKMAN@SKGF.COM

Box AF

Commissioner for Patents Washington, D.C. 20231

Re:

U.S. Utility Patent Application

Appl. No. 09/340,690; Filed: June 29, 1999

**Human Tumor Necrosis Factor Receptor-Like 2** 

Inventors: NI et al.

Our Ref: 1488.0770007/EKS/PAJ

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Reply Under 37 C.F.R. § 1.116;
- 2. One return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents January 22, 2002 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.


Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Peter A. Jackman Attorney for Applicants Registration No. 45,986

PAJ:aye Enclosures

P:\USERS\PJACKMAN\1488\077\7\pto 116 reply trn SKGF Rev. 11/01/01 mac





In re application of:

NI et al.

Appl. No. 09/340,690

Filed: June 29, 1999

For:

Human Tumor Necrosis Factor

Receptor-Like 2

Confirmation No.: N/A

1646 Art Unit:

Examiner: Kemmerer, E.

JAN & SOON SON Atty. Docket: 1488.0770007/EKS/P

**Reply Under 37 C.F.R. § 1.116** 

Attn: Box AF

Commissioner for Patents Washington, D.C. 20231

Sir:

In reply to the final Office Action dated October 22, 2001, (PTO Prosecution File Wrapper Paper No. 16), Applicants submit the following Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.